Elbling L - Search Results

1

Vaults and the major vault protein: novel roles in signal pathway regulation and immunity.

Berger W, Steiner E, Grusch M, Elbling L, Micksche M. Berger W, et al. Among authors: elbling l. Cell Mol Life Sci. 2009 Jan;66(1):43-61. doi: 10.1007/s00018-008-8364-z. Cell Mol Life Sci. 2009. PMID: 18759128 Free PMC article. Review.

2

The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals.

Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, Sutterlüty H, Berger W. Steiner E, et al. Among authors: elbling l. J Cell Sci. 2006 Feb 1;119(Pt 3):459-69. doi: 10.1242/jcs.02773. Epub 2006 Jan 17. J Cell Sci. 2006. PMID: 16418217

3

Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.

Berger W, Elbling L, Micksche M. Berger W, et al. Among authors: elbling l. Int J Cancer. 2000 Oct 15;88(2):293-300. Int J Cancer. 2000. PMID: 11004683

4

A small upstream open reading frame causes inhibition of human major vault protein expression from a ubiquitous mRNA splice variant.

Holzmann K, Ambrosch I, Elbling L, Micksche M, Berger W. Holzmann K, et al. Among authors: elbling l. FEBS Lett. 2001 Apr 6;494(1-2):99-104. doi: 10.1016/s0014-5793(01)02318-3. FEBS Lett. 2001. PMID: 11297743 Free article.

5

Overexpression of the human major vault protein in astrocytic brain tumor cells.

Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M. Berger W, et al. Among authors: elbling l. Int J Cancer. 2001 Nov 1;94(3):377-82. doi: 10.1002/ijc.1486. Int J Cancer. 2001. PMID: 11745417

6

Cellular functions of vaults and their involvement in multidrug resistance.

Steiner E, Holzmann K, Elbling L, Micksche M, Berger W. Steiner E, et al. Among authors: elbling l. Curr Drug Targets. 2006 Aug;7(8):923-34. doi: 10.2174/138945006778019345. Curr Drug Targets. 2006. PMID: 16918321 Review.

7

SP-transcription factors are involved in basal MVP promoter activity and its stimulation by HDAC inhibitors.

Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, Berger W. Steiner E, et al. Among authors: elbling l. Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43. doi: 10.1016/j.bbrc.2004.03.029. Biochem Biophys Res Commun. 2004. PMID: 15047174

8

Resistance against novel anticancer metal compounds: differences and similarities.

Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski MS, Elbling L, Micksche M, Keppler B, Berger W. Heffeter P, et al. Among authors: elbling l. Drug Resist Updat. 2008 Feb-Apr;11(1-2):1-16. doi: 10.1016/j.drup.2008.02.002. Epub 2008 Apr 3. Drug Resist Updat. 2008. PMID: 18394950 Review.

9

Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).

Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Körner W, Sevelda F, Micksche M, Keppler BK, Berger W. Heffeter P, et al. Among authors: elbling l. J Pharmacol Exp Ther. 2005 Jan;312(1):281-9. doi: 10.1124/jpet.104.073395. Epub 2004 Aug 26. J Pharmacol Exp Ther. 2005. PMID: 15331656

10

Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.

Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A, Micksche M. Berger W, et al. Among authors: elbling l. J Cancer Res Clin Oncol. 2005 Jun;131(6):355-63. doi: 10.1007/s00432-004-0653-9. Epub 2005 Jan 27. J Cancer Res Clin Oncol. 2005. PMID: 15856298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters